Key result
Morpholino-substituted anthracyclines increase activity against MDR tumors while Ring-B modifications show no benefit.
Activity on multidrug resistant tumors is driven by modifications in the sugar moiety rather than the aglycone ring-B of anthracyclines, though structural modifications remain important for reducing cardiotoxicity.
Answers are grounded in this paper and cite their sources.
May support anthracycline redesign to limit cardiotoxicity; leaves open optimal modifications against multidrug-resistant tumors.
One of the most investigated classes of antitumor drugs is represented by anthracyclines. Over thirty years since the original discovery of daunorubicin and doxorubicin thousands of anthracycline analogues have been synthesized and tested to identify compounds superior to the parent drugs in terms of increased therapeutic effectiveness, reduced toxicity or both. Previous structure-activity studies had shown that minor modifications of the anthracycline structure can result not only in active agents, but, more importantly, analogues with reduced cardiotoxicity and activity on multi drug resistance. The fact that 4-demethoxydaunorubicin showed higher potency than daunorubicin and a reduced cardiotoxicity, prompted us to explore novel analogues with altered substitution patterns on the anthraquinone system, particularly ring-B. In this review we will describe total synthesis and antitumor activity of three classes of derivatives: whereby one hydroxyl group in ring-B was either removed or replaced with nitro or amino groups. While these modifications yielded anthracyclines with a promising pharmacological activity, they did not modify activity on multidrug resistant (MDR) tumors. On the other hand, introduction of morpholino group in the sugar part of these new molecules, dramatically increased activity on MDR tumors. We conclude that activity on MDR tumors is not bound to modifications in the aglycone moiety of anthracyclines.
No takes yet. Share an insight, caveat, or question.
Suarato et al. (1999) conducted a review in Multidrug resistant (MDR) tumors. Ring-B modified anthracyclines was evaluated on Antitumor activity on multidrug resistant (MDR) tumors. Ring-B modifications of anthracyclines yielded promising pharmacological activity but did not modify activity on multidrug resistant tumors, whereas introducing a morpholino group increased activity.
Synapse has enriched 10 related papers. Consider them for comparative context: